Huons acquires U.S. patent of ‘nanodrop’
Huons(CEO Ki-Ahn Um) announced on the 25th that the company acquired the U.S. approval of the ‘nanodrops(HU-007)’ being developed with a Korean Phase III clinical trial.
The U.S. patent is the manufacturing method and therapy of the dermatologic nanodrop containing cyclosporine and trehalose, an...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
